Golimumab Medical Necessity Assessment in Rheumatoid Arthritis

Evaluation of Medical Necessity Criteria

The American College of Rheumatology recommends golimumab as a biologic DMARD that should be used in combination with methotrexate for optimal efficacy in patients with rheumatoid arthritis 1
The FDA-approved dosing for Simponi Aria in rheumatoid arthritis is 2 mg/kg given as an intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter, and should be given in combination with methotrexate 1
The absence of concomitant methotrexate use fails to meet medical necessity criteria for Simponi Aria, as stated in the FDA label and clinical guidelines 1

The American College of Rheumatology guidelines suggest that if methotrexate cannot be tolerated orally, subcutaneous administration should be considered before abandoning methotrexate altogether, with higher bioavailability and potentially fewer gastrointestinal side effects 2, 3, 4
Documentation of disease activity using validated measures, such as the Clinical Disease Activity Index or Disease Activity Score, is necessary to establish moderate-to-severe disease and meet medical necessity criteria for Simponi Aria 1

To meet medical necessity criteria for Simponi Aria, patients should be on concurrent methotrexate therapy unless specifically contraindicated, according to the American College of Rheumatology guidelines 1
Complete documentation of prior DMARD trials, responses, and reasons for discontinuation is essential for medical necessity determination, as recommended by the American College of Rheumatology 1

The American College of Rheumatology 2021 guidelines strongly recommend that biologic DMARDs like golimumab be used in combination with methotrexate for optimal efficacy 5
Patient demonstrates favorable response to prior golimumab administration, with documented improvement from pre-treatment PAIN 8/10 and RAPID3 6/10 to post-treatment PAIN 2/10 and RAPID3 2/10 5
Patient is over 18 years of age 5
Moderate to severe active rheumatoid arthritis documented with Disease Activity Score (RAPID3 5/10 at 5/6/2025 visit, which corresponds to moderate disease activity) 5
No concurrent use of abatacept, anakinra, or other TNF inhibitors documented 5
No active infection apparent at time of administration 5
Failed hydroxychloroquine monotherapy 5
Failed sulfasalazine 5
Failed leflunomide after initial response 5
Failed methotrexate due to widespread rash (though duration of trial not clearly documented) 5
Multiple NSAID failures documented 5
The American College of Rheumatology recommends a minimum of 3 months for each DMARD trial based on efficacy and tolerability 5
RAPID3 improvement from 6/10 to 2/10 indicates transition from moderate-high disease activity to low disease activity, which is the treatment target per ACR guidelines 5